Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura
NCT03222843Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Hengrui. Started Jun 2017; status: completed.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03222843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222843.